Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Alleviating carbohydrate counting for patients with type-1 diabetes using a closed loop system with weekly subcutaneous Semaglutide: a single-center placebo-controlled, randomized, 2x3 factorial design, outpatient trial

FY 2023-24

Summary
Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing cells, leading to insulin deficiency. Conventional treatments involve insulin pump therapy, yet maintaining optimal glycemic control remains challenging. Automated insulin delivery systems, such as closed-loop (CL) systems, adjust insulin delivery based on glucose levels and have shown promise in improving T1D management. However, they burden users with the constant need for carbohydrate counting during meals. Additionally, semaglutide (brand name: Ozempic), a glucagon-like peptide-1 receptor agonist, has shown promise in T2D management due to its ability to regulate blood sugar, promote weight loss, and provide protection for the heart and kidneys. There is potential that semaglutide has an even more pronounced impact in T1D management. This study will investigate whether weekly semaglutide injections can replace carbohydrate counting in T1D patients on CL therapy without compromising glucose control. This is a crossover, placebo-controlled, randomized, 2x3 factorial designed study with 26 participants receiving weekly semaglutide or placebo injections over 24 weeks. The first 12 weeks involve drug titration, followed by four different meal strategies in a randomized order: Carbohydrate counting, Simple meal announcement with i) Humalog and ii) with Lyumjev, and fully CL system. This study aims to provide valuable insights into the potential role of semaglutide in simplifying diabetes management for people with T1D using CL systems. If successful, it could alleviate the burden of carbohydrate counting and improve the quality of life for individuals with T1D. Additionally, it may contribute to better glycemic control and open avenues for innovative approaches in diabetes care.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506227
Name
Sabelli Nicholas
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Alleviating carbohydrate counting for patients with type-1 diabetes using a closed loop system with weekly subcutaneous Semaglutide: a single-center placebo-controlled, randomized, 2x3 factorial design, outpatient trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fully-Closed Loop System; Lyumjev; Ozempic; Semaglutide; Simple Meal Announcement; Type 1 Diabetes
Abstract
Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing cells, leading to insulin deficiency. Conventional treatments involve insulin pump therapy, yet maintaining optimal glycemic control remains challenging. Automated insulin delivery systems, such as closed-loop (CL) systems, adjust insulin delivery based on glucose levels and have shown promise in improving T1D management. However, they burden users with the constant need for carbohydrate counting during meals. Additionally, semaglutide (brand name: Ozempic), a glucagon-like peptide-1 receptor agonist, has shown promise in T2D management due to its ability to regulate blood sugar, promote weight loss, and provide protection for the heart and kidneys. There is potential that semaglutide has an even more pronounced impact in T1D management. This study will investigate whether weekly semaglutide injections can replace carbohydrate counting in T1D patients on CL therapy without compromising glucose control. This is a crossover, placebo-controlled, randomized, 2x3 factorial designed study with 26 participants receiving weekly semaglutide or placebo injections over 24 weeks. The first 12 weeks involve drug titration, followed by four different meal strategies in a randomized order: Carbohydrate counting, Simple meal announcement with i) Humalog and ii) with Lyumjev, and fully CL system. This study aims to provide valuable insights into the potential role of semaglutide in simplifying diabetes management for people with T1D using CL systems. If successful, it could alleviate the burden of carbohydrate counting and improve the quality of life for individuals with T1D. Additionally, it may contribute to better glycemic control and open avenues for innovative approaches in diabetes care.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sabelli, Nicholas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~